ArticleAntibiotics (Basel, Switzerland)2022
Prevalence and Genetic Analysis of Resistance Mechanisms of Linezolid-Nonsusceptible Enterococci in a Tertiary Care Hospital Examined via Whole-Genome Sequencing.
Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Novel transposon TnMicrobial genomics · 2026Article
- Novel transposon TnmedRxiv : the preprint server for health sciences · 2026Article
- Environmental occurrence of optrA-mediated linezolid resistance in Enterococcus isolates and genomic insights into Enterococcus faecium ST54 co-harboring optrA, poxtA, and cfr(D) genes.World journal of microbiology & biotechnology · 2026Article
- Phylogenetic and pathogenic description of Enterococcus faecalis at a Northern Chinese hospital.BMC microbiology · 2025Article
- Linezolid in the Focus of Antimicrobial Resistance ofInternational journal of molecular sciences · 2025Review
- Genomic and clinical characterization of linezolid resistance in Enterococcus species from cancer patients in China.BMC infectious diseases · 2025Article
- Molecular Epidemiology and Genetic Context ofAntibiotics (Basel, Switzerland) · 2025Article
- Genetic Characterization of a Linezolid- and Penicillin-ResistantTransboundary and emerging diseases · 2025Article
- Genomic Characterization and Phylogenetic Analysis of Linezolid-Resistant Enterococcus from the Nostrils of Healthy Hosts Identifies Zoonotic Transmission.Current microbiology · 2024Article
- Genomic epidemiology reveals multiple mechanisms of linezolid resistance in clinical enterococci in China.Annals of clinical microbiology and antimicrobials · 2024Article
- CHROMAgar™ LIN-R as an efficient screening tool to assess the prevalence of linezolid-resistant enterococci in German hospital patients-a multicentre study approach, 2021-2022.The Journal of antimicrobial chemotherapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Linezolid plays an important role in the treatment of invasive infections caused by vancomycin-resistant enterococci after its introduction to clinical practice. However, a detailed examination of linezolid-nonsusceptible enterococci (LNSE) is required. In this study, we attempted to analyze the mechanisms of LNSE strains isolated from a tertiary care hospital. (2) Methods: From 2019 to 2020, 18
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.